Literature DB >> 15769626

Culture conditions influence uptake and intracellular localization of the membrane permeable cGMP-dependent protein kinase inhibitor DT-2.

Kevin F Foley1, Sergio De Frutos, Kristina E Laskovski, Werner Tegge, Wolfgang R Dostmann.   

Abstract

The membrane-permeable peptide DT-2 which utilizes the HIV-Tat membrane translocation sequence is known to inhibit cGMP-dependent protein kinase (PKG) effectively in vitro and in various cell lines and tissue preparations. However, the uptake characteristics of DT-2 have not been studied in detail. We investigated the intracellular uptake and localization of fluorescein-labeled DT-2 (fDT-2) in cultured C6-glial cells and vascular smooth muscle cells (VSMCs) as well as VSMCs in intact arteries. To avoid fixation-induced fluorescence, live unfixed cells and arteries were incubated with fDT-2 and examined using conventional and confocal fluorescence microscopy. In non-differentiated cultured VSMCs, uptake appeared vesicular with nuclear exclusion, consistent with an endocytotic internalization mechanism. Inhibition of endocytosis by phenylarsine oxide (PAO), low temperature or disruption of actin polymerization by cytochalasin-D or lantrunculin-A showed a residual non-endocytotic fDT-2 translocation with diffuse cytosolic and nuclear uptake. Similarly, differentiated contractile VSMCs within the medial layer of intact cerebral arteries also showed a distinctively different, more diffuse cytosolic uptake and time dependent nuclear localization. To verify the morphology dependency of fDT-2 uptake, VSMCs were reconstituted in fibrillar collagen matrices. The cells adopted a differentiated morphology and fDT-2 translocation was similar to cells in intact arteries. These results demonstrate that VSMCs cells utilize distinct cellular uptake mechanisms depending on their phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769626     DOI: 10.2741/1620

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  5 in total

1.  Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase (PKGIalpha).

Authors:  Darja Lavogina; Christian K Nickl; Erki Enkvist; Gerda Raidaru; Marje Lust; Angela Vaasa; Asko Uri; Wolfgang R Dostmann
Journal:  Biochim Biophys Acta       Date:  2010-04-18

2.  (D)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha.

Authors:  Christian K Nickl; Shiv Kumar Raidas; Hong Zhao; Matthias Sausbier; Peter Ruth; Werner Tegge; Joseph E Brayden; Wolfgang R Dostmann
Journal:  Biochim Biophys Acta       Date:  2009-12-16

3.  Mode of action of cGMP-dependent protein kinase-specific inhibitors probed by photoaffinity cross-linking mass spectrometry.

Authors:  Martijn W H Pinkse; Dirk T S Rijkers; Wolfgang R Dostmann; Albert J R Heck
Journal:  J Biol Chem       Date:  2009-04-15       Impact factor: 5.157

4.  Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines.

Authors:  H Dan Lewis; Ali Husain; Robert J Donnelly; Dimitrios Barlos; Sheraz Riaz; Kalyani Ginjupalli; Adetola Shodeinde; Beverly E Barton
Journal:  BMC Biotechnol       Date:  2010-10-28       Impact factor: 2.563

5.  cGMP-Dependent Protein Kinase Inhibitors in Health and Disease.

Authors:  Stefanie Wolfertstetter; Johannes P Huettner; Jens Schlossmann
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.